There’s a constant push and pull on priorities when you’re an emerging player. Especially if it’s in the enzyme tech market. From the need to generate revenue in the near term through to maintaining a strong innovation process. And of course, you need alignment between senior management and board on the business model. In short you need a roadmap that covers all the bases.
As our client prepared for its next capital raise, they faced several challenges:
Ultimately, they needed a coherent story for investors that tied the long-term strategic vision together with:
We ran three parallel workstreams focusing on:
We ran an extensive primary research campaign that:
Additionally, the R&D and BD teams were trained to validate the commercial feasibility of ideas that were technically promising and could meet huge demand in the market.
The optimum business model was evaluated and presented to the board. Additionally, we created a structured assessment toolkit, which detailed:
And to manage filling the innovation pipeline. We designed and implemented a stage-gate process, which included estimating capital requirements to launch and scale. The client team was trained to run the process, ensuring consistency and continuity. Our approach and solution enabled senior management to present a compelling story for investors.